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Abstract
Cardiovascular disease, osteoporosis, and dementia are 
three disease processes that have been directly linked to 
estrogen deficiency. Cardiovascular disease (CVD) is the 
number one cause of death for all postmenopausal women, 
including those with end-stage renal disease (ESRD). 
Osteoporosis and dementia are disease processes that 
profoundly affect the quality of life for postmenopausal 
women. Currently, 34% of women in the general population 
receive hormone replacement therapy (HRT), while only 10% 
of women with ESRD receive this therapy. Therefore, the 
purpose of this descriptive study was to examine the 
facilitators and barriers of nephrology health care 
providers to initiation of HRT among their postmenopausal 
patients. Pender's Health Promotion Model was utilized for 
the theoretical framework. The research questions that 
guided the study were as follows: What are the barriers to 
nephrology health care providers initiating HRT on 
postmenopausal women with ESRD? And what are the 
facilitators to nephrology health care providers 
initiating HRT on postmenopausal women with ESRD? The
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target population was nephrology health care providers at 
outpatient hemodialysis facilities. Tramel's Questionnaire 
was utilized to collect data. The convenience sample (N =
2 6) consisted of subjects who completed and returned the 
questionnaire for a 17% return. Descriptive statistics, 
including frequency distribution, percentage, and ranking, 
were utilized to analyze the data. Nephrology health care 
providers were 80.77% (n — 21) male and practiced 
nephrology for an average 12.8 years. The average number 
of postmenopausal women under their care was 138, and 
42.31% (n = 11) reported prescribing HRT for these women. 
The number one ranked health facilitator to prescribing 
HRT was surgically-induced menopause. The need for more 
research in the area of HRT for women with renal failure 
was the number one ranked external facilitator. The number 
one ranked barrier to HRT initiation was a concern of 
physician liability. One implication for nursing is the 
need for continued research in the area of menopause for 
women with ESRD. Recommendations for further research 
included replication of this study with expanded 
geographical area and continued use of the research tool 
to establish reliability and validity.
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Dedication
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and the Father by him. Colossians 3:17
I dedicate this thesis as well as my life and work to
Jesus Christ, my Lord and Savior, for I know that it is
His Will that I work with patients who have renal failure.
For I was an hungred, and ye gave me no meat: I 
was thirsty, and ye gave me no drink: I was a 
stranger, and ye took me not in: naked, and ye 
clothed me not: sick, and in prison, and ye 
visited me not. Then shall they also answer 
him, saying. Lord, when saw we thee an hungred, 
or athirst, or a stranger, or naked, or sick, or 
in prison, and did not minister unto thee? Then 
shall he answer them saying. Verily I say unto 
you. Inasmuch as ye did it not to one of the 
least of these, ye did it not to me. Matthew 
25:42-45
Many dialysis patients are indigent; some have poor 
hygiene and very little clothing. Many rely on social 
services for transportation to and from hospitals and 
dialysis, doctor's appointments, the grocery store, and 
other personal business. Imagine having a stranger pick 
you up and take you home after a 2-week stay in the 
hospital. Often the only support they receive after 
getting home is a home health nurse (if they are lucky 
enough to qualify for this service) and one hot meal per
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day from "Meals on Wheels". For many dialysis patients the 
highlight of their week is coming to dialysis, for it may 
be the only socialization they receive; the only time 
someone touches them or speaks kindly to them. Being poor 
is a great trial in itself, as are the problems of living 
day to day with kidney failure. Coping with daily needs is 
enough, and often too much, without others looking down on 
you, especially health care providers. I became a nurse 
because I wanted to provide comfort and care for those in 
need. I vowed many years ago to care for my patients just 
as I would want my loved ones cared for.
We can and often do a lot of very good things to help 
others, but if there is no real caring for that person, 
then it is done to benefit ourselves in some way. Most 
people are like children; they know when you truly care 
and when you don't. Romans 13:8 says our first 
responsibility is to love : "Owe no man anything, but to 
love one another . . ."
This thesis is also dedicated to someone very special 
to me, my brother, David. I love you very much.
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A renewed interest in women's health care issues over 
the past several years has facilitated research about 
menopause and the use of estrogen. Many clinical trials 
have confirmed the benefits of hormone replacement therapy 
to postmenopausal women. Some of these benefits included 
relief of menopausal symptoms, reduction in the risk of 
osteoporosis, maintenance of bone mass, improvement in 
lipid profiles and cognitive function, and reduction in 
the risk of cardiovascular morbidity and mortality (Holly, 
Schmidt, Bender, Dumler, & Schiff, 1997). In addition, 
recent studies have shown that the use of hormone 
replacement therapy (HRT) can prevent, lessen the severity 
of, or reverse dementia, particularly Alzheimer's disease 
(Brinton, 1997).
Although the average age for women to be in a state 
of menopause has remained unchanged at 51.4 years, life 
expectancy has increased. By the year 2003, a woman can 
expect to live an average of 80 years; today women may 
live one third to one half of their lives past menopause
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in an estrogen deficient state (Lobo, 1999). Because of 
the benefits of HRT, its use in the general population has 
increased during the past 20 years. Currently, 34% of 
postmenopausal women in the United States are prescribed 
HRT. Within this population only 10% of postmenopausal 
women with end-stage renal disease (ESRD) receive a 
prescription for HRT from their health care provider even 
though the mean age for menopause is decreased to 47 years 
in these patients (Holly et al., 1997).
The population of postmenopausal women in the United 
States is climbing at an exponential rate. In 1990 there 
were 28.7 million women older than 55 years of age; by the 
year 2020 this group is estimated to be 45.9 million. In 
1999 over 31 million women began the menopausal transition 
(Lobo, 1999). As the general population ages, the number 
of postmenopausal women with ESRD also will increase. The 
prevalence rate for ESRD among postmenopausal women was 
607 per million in 1991 and had climbed to 931 per million 
in 1997 (Mattix & Singh, 2000). Cardiovascular disease 
(CVD), osteoporosis, and dementia are three disease 
processes that profoundly affect the quality of life and 
health of ESRD patients who are menopausal (D. Arnold, 
personal communication. May 14, 2001). Nephrology health 
care providers have ignored the issue of HRT in their 
postmenopausal patients despite mounting evidence that
3
estrogen therapy could possibly decrease morbidity and 
mortality and positively influence quality of life (Mattix 
& Singh, 2000). In an effort to better understand the 
disparity of HRT prescription in women with ESRD, this 
researcher explored the prescription practices of 
nephrology health care providers regarding initiation of 
HRT.
The American Association of Clinical Endocrinologist 
(AACE) has cited the following primary goals for HRT: 
relief of menopausal symptoms and prevention of 
cardiovascular disease, osteoporosis, and dementia. Some 
common menopause related symptoms that are relieved by HRT 
are hot flashes, decreased libido, depression, headache, 
insomnia, mood swings, nervousness, myalgia, and 
formications. Therapeutic levels of estrogen decrease the 
risk of cardiovascular disease, osteoporosis, and 
cognitive dysfunction ("Managing Menopause," 2000). 
Sufficient data exist to suggest that all-cause mortality 
is decreased in women who take HRT, mainly because of the 
decrease in heart disease (Lobo, 1999). The AACE has 
recommended that all postmenopausal women consider HRT as 
preventive medicine ("Managing Menopause," 2000). Existing 
research data and the AACE's position are considered 
facilitating factors for initiating HRT for women by 
health care providers.
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Cardiovascular disease is the number one cause of 
death in all postmenopausal women and the number one cause 
of morbidity and mortality in women with ESRD. 
"Cardiovascular disease in ESRD patients has reached 
epidemic proportions" (Mattix & Singh, 2000, p. 207). From 
1995 to 1997 CVD accounted for more than 80% of deaths in 
ESRD patients over the age of 65 and 42% of all deaths in 
women age 45 to 64 years. The risk for CVD is increased 
threefold for women after menopause, thus menopause may be 
related to this high rate of death due to CVD in women 
with ESRD (Mattix & Singh, 2000). After menopause, women 
experience an accelerated rate of cardiovascular events, 
as well as a decrease in high-density lipoproteins (HDL) 
and an increase in low-density lipoproteins (LDL).
Numerous studies have evaluated the effect of HRT on 
cardiovascular function. In 1997 Grodstein, Stampfer, and 
Coldita determined that after 15 years of estrogen 
replacement, risk of death by cardiovascular disease (CVD) 
was reduced by nearly 50%, and overall death was reduced 
by 40%. Some researchers credit these positive 
cardiovascular effects on the ability of estrogen to 
maintain lipoproteins at healthier levels through its 
interaction with proteins in the liver (Ginsburg et al.,
1998) . Other researchers believe that estrogen has a 
direct effect on blood vessels by reacting with receptors
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on the vessel walls (Women's Health, 2000). Ginsburg et 
al. (1998) found that women with ESRD and coronary artery 
stenosis who received estrogen replacement at any time had 
a decrease in risk of death up to 27%.
HRT has been a preventative measure for the 
development of osteoporosis, a condition in which bones 
become thin, fragile, and fracture easily as a result of 
low bone mass. The decline in bone mass that occurs with 
estrogen deficiency is caused by osteoclastic activity 
(increased resorption) which becomes uncoupled from 
osteoblastic activity (bone formation). The deficiency 
also has an indirect effect on parathyroid hormone and 
cytokines, which oppose the resorptive effects. The 
positive effects of estrogen on growth factors, 
calcitonin, vitamin D metabolism, and calcium absorption 
also are diminished in estrogen deficient women (Lobo,
1999).
As a result of an estrogen deficiency, and at an 
annual cost of $10 billion, approximately 800,000 U.S. 
women fracture a vertebrae or hip, and an estimated 12% to 
20% of these women do not survive the 6 months following 
the fracture. In a 1995 study, Lyhne and Pedersen 
evaluated the treatment of renal osteodystrophy in 23 
dialysis patients. The researchers found that women 
demonstrated a significant decrease in bone mineral
6
content as compared to men. The bone mineral content 
decrease for females was 6% per year, but was 
insignificant for males in the study. Comparable findings 
in the general population have shown that bone mineral 
content decreases 1% per year in females 35 to 65 years of 
age and 2% per year in perimenopause (Lyhne & Pedersen, 
1995). The significant difference in female bone mineral 
content suggests severe skeletal imbalances and could be 
related to sex hormone imbalances. The U.S. Food and Drug 
Administration (FDA) has approved the use of estrogen for 
the prevention of osteoporosis which currently is the most 
effective therapy for the prevention and treatment of 
osteoporosis (Women's Health, 2000).
Although the life expectancy of women is greater than 
men, women suffer greater negative consequences of the 
aging process than men. One such consequence is dementia, 
particularly Alzheimer's disease. In a 1996 study, Birge 
found that women were three times more likely to develop 
dementia than men, and women with CVD were five times more 
likely to develop dementia than women with no CVD. These 
data show that women have a higher risk for developing 
dementia than men and that a medical insult, such as 
myocardial infarction, stroke, or renal failure, may 
exacerbate dementia in women (Brinton, 1997).
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Past authors on aging and dementia have shown that 
estrogen positively affects cognitive function; however, 
recent authors have produced evidence that estrogen delays 
the onset and progression of Alzheimer's disease. Five 
epidemiologic studies conducted from 1994 to 1996 
demonstrated a 4 0% to 60% reduction in the risk of 
Alzheimer's disease in women who had taken HRT (Hammond, 
1999). Women treated with estrogen demonstrated a 
significant memory improvement and delay in cognitive 
loss. For example, in 1996 Tang et al. conducted a study 
of 1,124 women who were followed from 1 to 5 years. The 
study demonstrated that women who took estrogen for one 
year had a dramatic delay in the onset of Alzheimer's 
disease. The researchers also determined that women who 
only briefly took HRT for menopausal symptom control 
experienced this delay in onset. Thus, it is speculated 
that even brief exposure to estrogen prevents irreversible 
loss of neurons and thereby influences the expression of 
Alzheimer's disease (up to 30 years later). Recent studies 
have shown that estrogen stimulates the expression of 
neurotrophic factors, protects neurons from toxicity, 
stimulates axonal regeneration, and stimulates the 
production of acetylcholine and serotonin (Hammond, 1999).
Early studies on the reproductive function of female 
dialysis patients found the majority of these women to be
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amenorrheic with no ovarian function. Results of studies 
conducted in the 1980s were that only 10% of premenopausal 
women had regular menses, but few studies have been done 
since 1987, when erythropoietin was introduced to the ESRD 
community. Erythropoietin is a hormone produced by the 
kidney to stimulate production of red blood cells; 
patients with ESRD were severely anemic prior to its 
introduction in 1987 (D. Arnold, personal correspondence.
May 10, 2001). The etiology of ovarian failure is poorly 
understood but is thought to be hypothalamic in origin and 
possibly related to the elevated levels of prolactin 
associated with renal failure. In 1997, Holly et al. 
conducted a study of 7 6 premenopausal women receiving 
dialysis at four outpatient dialysis facilities in the 
United States. The researchers' purpose was to identify 
menstrual patterns, contraception, HRT use, and sexuality 
issues. Women age 55 years and older when beginning 
dialysis were excluded from the study. Contrasted to 
earlier reports that only 10% of premenopausal dialysis 
patients menstruate regularly, Holley et al. found 42% (n 
=32) of the subjects had regular periods. The sample 
(59%, n = 45) of women with ESRD also reported having 
irregular periods, and 64% (14 of 22) of the subjects
reported heavy menstrual flow with clots. Of the sample
9
(N = 76), 19 were postmenopausal. Of these, 5 reported 
menopause occurring after starting dialysis.
In the same year, Cochrane and Regan (1997) undertook 
a prospective study to establish the nature and extent of 
gynecological disorders among 100 women with ESRD, 
including transplanted patients. The researchers found 
that of the 62 subjects who were menstruating, 81% (n =
50) had menorrhagia and 35% (n = 33) were amenorrheic. Of 
the 35 menopausal women in the study, 20% (n = 7) were 
less than 40 years of age and only 2 were on HRT. A total 
of 49 women enrolled in the study were less than 40 years 
of age; of these, 14% had primary ovarian failure.
Prolactin levels in all subjects were normal except for 
those on hemodialysis which were elevated. The researchers 
concluded that 85% of these patients had menstrual 
disorders, mainly menorrhagia, which was of concern 
because heavy vaginal bleeding worsened the anemia of 
ESRD. Of the women identified as menopausal, all were 
recommended to initiate HRT. Cochrane and Regan determined 
that contraceptive counseling had been inappropriate or 
nonexistent and recommended all women with ESRD seek 
contraceptive counseling. Low-dose combined oral 
contraceptives were prescribed for most patients which had 
the added benefit of improved cyclic control. The 
eightfold increase in cervical dyskariosis among sample
10
women was thought to be related to the use of 
immunosuppressive drugs. Of significance is the fact that 
80% of these abnormalities would have been missed had the 
researchers not preformed cervical smears on all patients. 
Cochrane and Regan (1997) confirmed the value of regular 
gynecological surveillance for seemingly asymptomatic 
women with chronic renal failure based on the unrecognized 
pathology identified in the study.
Hyperprolactinaemia is frequent in women with ESRD 
and associated with decreased oestadiol levels, decrease 
in sexual function, and depression. In 1999, 
Matuszkiewicz-Rowinska et al. documented the benefits of 
biweekly transdermal oestradine in premenopausal estrogen 
deficient women on dialysis. The researchers concluded 
that normalization of oestradiol levels caused a fivefold 
reduction in prolactin/oestradiol ratio accompanied by an 
increase in general well-being, sexual function, libido, 
and physical activity (Matuszkiewicz-Rowinska et al.,
1999).
The AACE, as well as other professional 
organizations, has recommended that all postmenopausal 
women consider HRT as preventive medicine. The primary 
contraindications to HRT are a history of breast or 
endometrial cancer, stroke, heart attack, liver disease, 
history of venous thrombosis, and undiagnosed vaginal
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bleeding. Relative risks are smoking, hypertension, benign 
breast and uterine disease, endometriosis, pancreatitis, 
epilepsy, and headaches (Women's Health, 2000). HRT is not 
without risks, including endometrial disease, breast 
cancer, vaginal bleeding, somatic complaints (breast 
tenderness), and idiosyncratic reactions, such as 
hypertension and venous thrombosis. These risks must be 
weighed against the potential benefits for each individual 
client on a case-by-case review (Lobo, 1999).
The documented benefits of HRT are numerous; however, 
the rate of HRT prescription remains low among women with 
renal failure. The purpose of this research, therefore, 
was to identify the facilitators and barriers to HRT 
prescription among these women. Possible barriers to 
health care providers prescribing HRT for women with ESRD 
include the perception that they are unlikely to benefit 
from HRT because of chronic illness and or shortened life 
span or because they may have a higher risk of adverse 
effects of estrogen (Andreoli, 2000). Factors such as 
physician attitude, ethnicity, secular trend, and 
geographic location also could explain the overall low 
rate of HRT among postmenopausal women with ESRD (Gillen, 
Gipson, & Stehman-Breen, 1999). Another barrier to 
consider might be physician's lack of knowledge concerning 
HRT, such as dose and type to prescribe. Nephrologists are
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specialists and may view HRT as primary care, and they opt 
not to prescribe for this reason. Further considerations 
of comorbid conditions, such as CVD, diabetes, peripheral 
vascular disease, and clotting disorders, also may be 
barriers to initiation of HRT in postmenopausal women on 
dialysis. Nephrologists are 95% male, which could be a 
barrier to initiation of HRT in itself, as they simply may 
never consider menopause or consider it outside their 
realm of practice. In addition, nephrologists may focus 
only on correction of medical problems relevant only to 
ESRD (D. Arnold, CFNP, personal communication. May 10,
2001). Facilitators to HRT initiation would include 
nephrology health care providers believing and practicing 
in health-promoting behaviors. Their beliefs about primary 
prevention and benefits to health-promoting behaviors will 
impact the way they practice. If they perceive HRT as 
having prophylactic uses, they will be more likely to 
prescribe.
Significance to Nursing
The documented benefits of HRT may have significance 
for postmenopausal women with ESRD. The younger age for 
entering menopause in this population of patients removes 
the protective cardiovascular, cognitive, and bone mass 
effects of estrogen. Women with ESRD have a higher risk
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for cognitive dysfunction, renal osteodystrophy, 
accelerated atherosclerosis, and cardiovascular disease 
compared to the general population. Cardiovascular disease 
accounts for nearly half of the mortality in dialysis 
patients each year. The potential benefits of HRT for 
women with ESRD are numerous. The cardiovascular 
protective effects alone could significantly decrease 
related morbidity and mortality, as well as a substantial 
decrease in associated health care costs (Gipson, 1999).
Nephrology health care providers are in a unique 
position to initiate HRT as dialysis patients are seen by 
physicians and nurse practitioners on a weekly basis. By 
viewing HRT as preventive medicine, these health care 
providers could dramatically impact related morbidity and 
mortality in postmenopausal women with ESRD, as well as 
improve their quality of life by decreasing depression and 
enhancing mood. Nurse practitioners are educated to assess 
and treat women holistically. The nephrology nurse 
practitioner could augment the care of these women not 
only in the area of HRT, but also in the areas of 




Pender's Health Promotion Model was used as the 
theoretical framework for this study (1987). The Health 
Promotion Model contains concepts relevant to health- 
promoting behaviors with the goal of nursing to support 
the achievement of optimal health for each person. Pender 
identified behaviors and mechanisms for enhancing health 
called cognitive-perceptual factors. These factors include 
importance, control of, definition, and perceived status 
of health. In addition, self-efficacy and perceived 
benefits and barriers to health-promoting behaviors are 
factors that directly impact health-influencing behaviors. 
Rather than let disease happen when it is avoidable,
Pender emphasized disease prevention. When health 
promotion and prevention fail to prevent disease, the 
priority then shifts from primary to secondary and 
tertiary care (Pender, 1987). Often an acute illness turns 
into a chronic, devastating disease that could have been 
prevented by early utilization of health promotion and 
disease prevention concepts.
The purpose of this study was to identify the 
facilitators and barriers to nephrology health care 
providers initiating HRT in postmenopausal women with 
ESRD. Researchers have established that HRT initiation in 
postmenopausal women can prevent CVD, osteoporosis, and
15
dementia as well as numerous other benefits. Therefore, 
Pender's Health Promotion Model was utilized as a guide to 
investigate the health-promoting behavior for initiating 
HRT among postmenopausal women with ESRD for health care 
providers. The beliefs of nephrology health care providers 
about primary prevention, importance of health, and 
perceived benefits to health-promoting behaviors are 
concepts from the Health Promotion Model that are 
applicable to this study.
Nurse practitioners and nephrologists working with 
ESRD must buy into the perceived benefits of HRT.
Endorsing this concept could make them more apt to refer, 
teach, council, and assess their postmenopausal patients 
for signs of estrogen deficiency. Another concept in the 
Health Promotion Model is importance of health; if health 
care providers recognize HRT as important to health, they 
could be more apt to prescribe. If they support the 
benefits of HRT, this is a facilitator; if they do not, it 
is a barrier.
In Pender's revised Health Promotion Model (1996), 
the term immediate competing demands and preferences 
replaced the concepts of benefits and barriers. Competing 
demands refer to conflicts over which the individual 
(health care provider) has low control. Chronic illness 
and comorbidity associated illness of ESRD patients might
16
be competing demands for the initiation of HRT in this 
population of patients. Breast cancer or preexisting 
cardiovascular disease are contraindications to the 
initiation of HRT and would therefore be considered a 
competing demand (barrier). Behaviors with high personal 
control refers to preferences (facilitator). A preference 
in this study would be the health care provider's belief 
that HRT has prophylactic uses, such as prevention of CVD, 
osteoporosis, and dementia (Pender, 1996).
Pender ascertains that health promotion and disease 
prevention should be the primary focus in health care. The 
current researcher agrees and considers HRT as a health 
promotion and disease prevention strategy for 
postmenopausal women with ESRD. In addition to reduced 
morbidity and mortality, initiation of HRT to women on 
dialysis may significantly improve their quality of life 
by decreased menopausal symptoms, increased libido and 
sexual function, improved physical activity, and an 
enhanced sense of well-being. These are factors that are 
considered to be health-enhancing (Tomey & Alligood,
1998).
Assumptions
The assumptions of the study were as follows:
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1. Estrogen replacement is the most effective therapy 
against osteoporosis.
2. HRT plays a role in decreasing the cardiovascular 
related mortality of postmenopausal women.
3. Women who are postmenopausal and have ESRD would 
benefit from HRT.
4. Nephrology health care providers can describe 
their prescribing practices of HRT.
-5. Health-promoting behaviors among nephrology health 
care providers are influenced by competing demands and 
preferences.
Statement of the Problem
Currently, only 10% of postmenopausal women with ESRD 
are prescribed HRT, while 34% of women in the general 
population are prescribed HRT. As HRT may contribute to 
the reduction of morbidity and mortality in patients with 
ESRD, the barriers and facilitators to nephrology health 
care providers initiating HRT should be addressed. 
Therefore, this researcher focused on the facilitators and 
barriers to the initiation of HRT in postmenopausal women 
with ESRD by nephrology health care providers.
Research Questions
This study addressed the following research 
questions :
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1. What are the barriers cited by nephrology health 
care providers to initiate HRT for postmenopausal women 
with end-stage renal disease?
2. What are the facilitators cited by nephrology 
health care providers to initiate HRT for postmenopausal 
women with end-stage renal disease?
Definition of Terms
For the purpose of this study, the following terms 
were defined for clarity of application:
1. Barriers : Theoretical: factors which obstruct or 
impede. Operational: factors which obstruct or impede 
nephrology health care providers from initiating HRT in 
postmenopausal women with end-stage renal disease as 
identified on Tramel's Questionnaire.
2. Nephrology health care providers: Theoretical: 
physicians and nurse practitioners who care for clients 
with end-stage renal disease. Operational: physicians and 
nurse practitioners who care for clients with end-stage 
renal disease and reside in Alabama, Mississippi, and 
Tennessee.
3. Hormone replacement therapy: Theoretical: daily 
replacement of conjugated estrogen and or
medroxyprogesterone acetate (MPA) to alleviate symptoms of 
menopause or as prophylaxis for disease prevention.
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Operational: daily replacement of conjugated estrogen and 
or medroxyprogesterone acetate (MPA) to alleviate symptoms 
of menopause and prophylaxis for disease prevention as 
identified on Tramel's Questionnaire.
4. Postmenopausal women: Theoretical: females who 
have experienced cessation of menses for more than 12 
months. Operational: females who have experienced 
cessation of menses for more than 12 months and have ESRD.
5. End-stage renal disease: Theoretical : a 
progressive, irreversible renal function deterioration in 
which the body’s ability to maintain metabolic and fluid 
and electrolyte balance fails, resulting in uremia, and 
requiring dialysis or renal transplantation. Operational: 
a progressive, irreversible renal function deterioration 
which requires dialysis or renal transplantation. This 
deteriorated disease must have been diagnosed in females 
for more than 6 months.
6. Facilitator: Theoretical: a factor that makes a 
task easier. Operational: a factor which would make it 
easier for nephrology health care providers to initiate 




The purpose of this study was to identify 
facilitators and barriers to HRT of postmenopausal women 
with end-stage renal disease. Recent studies have shown 
that HRT is under-prescribed in this population of 
patients. Estrogen deficiency predisposes women to serious 
health problems while estrogen replacement therapy can 
prevent or postpone major health problems, such as 
Alzheimer's disease, osteoporosis, and cardiovascular 
disease. There is a need for more research in the areas of 
menopause, estrogen deficiency, and hormone replacement in 
women with end-stage renal disease (ESRD).
Chapter II will provide a review of literature. 
Chapter III will describe methodology used for this study.
Chapter II 
Review of the Literature
Studies specifically addressing hormone replacement 
therapy (HRT) in women with end-stage renal disease (ESRD) 
have been limited. Studies available for substantiating 
the need for this research, relaying expertise on the 
subject, and providing conclusions for guiding the 
direction of this research are presented in this chapter. 
Established researchers reviewed were focused on concerns 
with potential cardiovascular and bone sparing effects of 
HRT as well as gynecological issues of women with ESRD.
Hyperprolactinaemia is common among women with ESRD 
and is associated with decreased osestadiol levels, 
decrease in sexual function, and depression. 
Matuszkiewica-Rowinska et al. (1999) conducted a study in 
Warsaw, Poland, to document the benefits of HRT in 
premenopausal women on hemodialysis with oestrogen 
deficiency. The aim of the study was to evaluate the 
effect of HRT on sexual function, serum 17B-oestradiol and 
prolactin levels, and bone mineral density.
2 1
22
The researchers enrolled 23 women for this 12-month 
study; subjects were divided into two groups. Group I 
consisted of 13 women and was the treatment group. They 
received biweekly transdermal oestradine with cyclic 
addition of norestisterone acetate (Estracomb TTS 50/0.25; 
Norvartis). Group II was the control group and consisted 
of 10 women who received no treatment. Entry criteria 
included the following: secondary amenorrhea, serum 17B- 
oestradiol concentration < 30 pg/ml, and on hemodialysis 
at least 6 months. A serum PTH > 400 pg/ml, treatment in 
prior 3 months with Vitamin D analogues, and 
immobilization or corticosteroid therapy for the previous 
12 months were exclusion criteria. In addition, diffuse 
fibrocystic disease of the breast, endometrial 
hypertrophy, and treatment with sex hormones for the 
previous 5 years excluded subjects. The etiology of renal 
failure for all subjects were glomeruli and interstitial 
nephritis, polycystic kidney disease, diabetic 
nephropathy, and other renal causes. These were 
distributed equally in both groups.
All subjects received baseline mammography and 
endometrium biopsy. In addition, seruml7B-oestradiol 
(normal range for follicular phase = 25-75 pg/ml), and 
prolactin (normal range = 66-4 90 mlU/ml) levels were drawn 
at baseline and 1, 3, 6, and 12 months in Group I, and
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before and after the study in Group II. Pre-dialysis serum 
calcium, alkaline phosphate, and routine biochemistries 
were assayed every 3 months, and serum triglycerides, LDL, 
and HDL every 6 months. Intact PTH levels and bone mineral 
density of the lumbar spine (L2-L4), femoral neck, and one 
third distal radius were measured in all subjects before 
and after the study. In addition, every 3 months all 
subjects received a general physical and gynecological 
examination as well as an interview. They were asked to 
rate themselves on questions concerning libido, sexual 
activity, physical fitness, appetite, mood, self respect, 
and general well-being. Statistics were calculated 
utilizing student t tests for paired samples, with p < .05 
taken as significant, and values were expressed as mean + 
SD.
Matuszkiewicz-Rowinska et al. (1999) found after 1 
month of treatment an increase in 17B-oestradiol from 
20.47 + 11.69 pg/ml to 46.8 + 13.6 pg/ml (p < .001) for 
Group I. Also, of significance was a progressive reduction 
of serum prolactin concentration from 1457 + 1045 to 691 + 
116 mlU/ml after 12 months of treatment with oestrogen- 
progestin therapy. Thus, the prolactin/oestradiol ratio 
decreased from 71.0 to 13.7 (p < .001). There was no 
change in PTH, alkaline phosphate, calcium, hematocrit, 
routine biochemistries, or blood pressure readings. The
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only change in lipid profile was a moderate increase in 
mean serum HDL-cholesterol (p < .01) in the treatment 
group. In both groups, the baseline bone mineral density z 
scores were depressed, with the lowest areas found at the 
lumbar spine. In Group I, an increase in bone mineral 
density at all three sites was noted with significant 
increases at L2-L4 (p < .05). The other two site increases 
were not significant. Control Group II experienced a mild, 
insignificant decrease in bone mineral density. The bone 
mineral density comparison of both groups after 12 months 
revealed marked differences in all three sites : distal 
radius (p < .01), femoral neck (p < .02), and L2-L4 (p < 
.05). The researchers concluded that normalization of 
serum oestradiol levels in women with previous oestradiol 
deficiency is sufficient to prevent bone loss and increase 
bone formation.
In addition, Matuszkiewicz-Rowinska et al. (1999) 
discovered a substantial improvement in sexual function in 
Group I compared to Group II. All of the women in Group I 
experienced regular menses, two women in the control group 
experienced a resumption in menstruation, but had 
irregular cycles. Also in the treatment group, 11 out of 
13 women reported a marked increase in libido, and 6 out 
of 8 women who were in stable relationships either resumed 
sexual intercourse or had a substantial increase in their
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sexual activity. These women also reported an increase in 
physical well-being, activity, mood, mental alertness, and 
self-respect.
The researchers concluded that normalization of 
oestradiol levels in premenopausal women on hemodialysis 
caused a fivefold reduction in prolactin/oestradiol ratio. 
These changes were accompanied by an improvement in 
general well-being, restoration of regular menses, and a 
marked improvement in sexual function. Also, of 
significance was an increase in bone mass with inhibition 
of bone demineralization. The researchers suggested that 
oestrogen deficiency has an important role in ureamic bone 
disease in premenopausal, amenorrheic women on dialysis.
The long survival rate of ESRD patients has caused an 
increased prevalence of complications that can strongly 
influence their quality of life. Hyperprolactinaemia is 
frequent in these patients and associated with a decreased 
oestradiol level and a decrease in sexual function. 
Depression also is frequent in this population of 
patients. Decreased oestradiol levels and sexual 
dysfunction may contribute to this depression as well as 
decrease the perceived quality of care. This current 
researcher finds Matuszkiewicz-Rowinska et al.'s study 
applicable to the current research because their results 
demonstrate that HRT increases general well-being.
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physical activity, libido, and sexual function. These 
factors have a significant role in the quality of life of 
these patients.
Of particular interest to the current researcher was 
the high mortality rate related to cardiovascular disease 
in women with ESRD. Therefore, studies exploring this 
topic were reviewed.
Ginsburg et al. (1998) conducted a study at Brigham 
and Women's Hospital in Boston. The researchers 
hypothesized that estrogen replacement therapy will 
improve lipoproteins in postmenopausal women with ESRD.
The purpose of the study was to examine the effects of 
estrogen therapy on lipoproteins.
Included in the study were women > 4 5  years old who 
had been on hemodialysis > 6 months. Additional criteria 
included hematocrit > 22%, normal hepatic transaminase, 
and a follicle stimulating hormone > 40 lU/ml. History of 
previous CVA, breast cancer, and current diabetes mellitus 
requiring insulin were exclusion criteria. Of the 11 
subjects who completed the study, the mean age was 61.4 + 
2.7 years, 8 were African American, 1 was Hispanic, and 2 
were White. Two subjects had noninsulin-dependent diabetes 
mellitus. No subject received any estrogen replacement 
therapy for 6 weeks prior to the study.
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Because of concerns of excess sex hormone levels, a 
desire to minimize patient risk and the need to assess 
lower dose estrogen replacement therapy, seven subjects 
entered a pilot study to evaluate estradiol levels 
attained on 1 mg oral estradiol daily for 4 weeks. Based 
on the results of this pilot study, 13 subjects entered a 
double-blind crossover study using oral micronized 
estradiol 2 mg and a placebo. The subjects were randomized 
to receive either the placebo or estrogen daily for 8 
weeks. After a 4-week washout period, subjects received 
the other therapy for 8 weeks. After completing the 8 
weeks of placebo estrogen, all subjects took 
medroxyprogesterone acetate 10 mg daily for 1 week.
Fasting blood samples were drawn at the initiation of 
the hemodialysis treatment at three different times in the 
study. The first was baseline or pre-intervention, then, 2 
days during the fourth week of intervention, and lastly, 3 
days during the last week of intervention. The results 
from each week were averaged and analyzed at the Lipid 
Research Lab of the Nutrition Department at Harvard School 
of Public Health. The following blood tests were done: 
total cholesterol, HDL, HDL2, HDL3, LDL, triglycerides, 
estradiol, VLDL (including apolipoprotein Al) estradiol, 
estrone, albumin, and sex hormone binging globulin (SHBG).
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The pilot study group who took estradiol 1 mg daily 
for 4 weeks was compared to the group taking 2 mg per day. 
Comparisons were considered statistically significant at p 
< .05. The estradiol levels in the 1-mg group increased 
from 21 + 6 to 91 + 19 (p = .024). In comparison to the 
placebo group, statistically significant increases in 
estradiol, estrone, and SHBG were achieved. Total HDL 
increased in all groups (1 mg estradiol, 2 mg estradiol, 
and placebo), the mean values were 16.1%. Total HDL 
concentration increased from 52.2 + 19.4 mg/dl after 
placebo treatment to 60.6 + 19.6 mg/dl (p = .046). HDL3 
increased by only 9.2% and was not statistically 
significant. LDL cholesterol was unchanged for all groups. 
Apolipoprotein Al increased by 24% (p = .0002), and total 
tryglycerides increased by 15.8% with daily estradiol. 
However, compared to the placebo group, neither was 
statistically significant.
Ginsberg et al. (1998) found that oral estradiol 
increases total HDL by an average of 8.4 mg/dl (16.1) and 
apolipoprotein Al by 24.6% compared with the placebo 
group. Previous studies in patients with no renal failure 
have suggested that comparable increases in HDL are 
expected to decrease the risk of cardiovascular disease by 
50%. The 1-mg dose of estradiol for 4 weeks increased HDL 
by 20%, which also is a level of response that would be
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expected to decrease cardiac morbidity and mortality. The 
researchers advocated the use of 1-mg estradiol dose for 
future trials to minimize the risks associated with higher 
hormone levels.
Many treatments for hyperlipidemia in the ESRD 
population have been evaluated, including gemfibrozil, 
probucol, lovastatin, and simvastatin. Many of these 
lipid-lowering agents have major side effects, such as 
rhabdomyolysis and elevated hepatic transaminases. The 
researchers concluded that similar benefit from estrogen 
replacement therapy may be achieved with fewer side 
effects.
Ginsburg et al. (1998) did not address the question 
of whether improvements in lipoprotein parameters could 
lead to comparable reductions in cardiac mortality. Larger 
clinical trials are needed to determine if estrogen 
replacement therapy should be routinely prescribed for 
postmenopausal women with ESRD. The current researcher 
finds this study applicable to her effort because the 
benefits of estrogen replacement therapy have been clearly 
demonstrated to reduce the risk of cardiovascular 
mortality in postmenopausal women with normal renal 
function. Because of the high mortality rate associated 
with postmenopausal women with ESRD, estrogen therapy 
should be considered for these patients. However, this
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possible benefit must be weighed against side effects of 
estrogen replacement therapy, such as venous 
thromboembolism, cholelithiasis, and increased risk of 
breast cancer.
The current researcher sought studies which 
identified reproductive and or genealogical issues in 
patients with ESRD. In a study which focused on 
gynecological disorders in women with renal failure, 
Cochrane and Regan (1997) undertook a prospective study 
which aimed to establish the nature and extent of 
gynecological disorders among 100 women with CRF (chronic 
renal failure) and or who had received a renal transplant.
Subjects were referred to the gynecology clinic by 
the nephrologists. They completed a detailed questionnaire 
concerning their renal disease, treatment, and 
gynecological history. They also underwent a pelvic exam 
and ultrasound, cervical smear, and serum FSH, LH, 
oestradiol, and prolactin levels. Women 50 and older had a 
mammogram. Of the sample (N = 100), 44 had a functioning 
renal transplant (mean age 39.6 years), 30 were managed by 
drug therapy (mean age 35.9), 17 were on hemodialysis 
(mean age 43.6), and the other 9 were on peritoneal 
dialysis (mean age 42.4). Nearly 40% of the women were 
referred for menstrual disorders, 12% for menopausal 
symptoms, 13% for subfertility, 11% for contraceptive
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counseling, and 2% for abnormal cervical smears. Only 23% 
of these subjects were referred for screening and 
surveillance.
The researchers found that of the 62 women who were 
menstruating, 81% had menorrhagia and 35% were 
amenorrheic. Of the 33 women with amenorrhea, 30 were 
menopausal. Only 12% of the 100 women had a normal 
menstrual cycle. Twelve women were referred with a 
diagnosis of menopause, but after examination of all 
subjects, the researchers discovered 23 women who were 
menopausal. Of these women (n = 35), 20% were less than 40 
years old, and only two were on HRT. A total of 4 9 women 
were enrolled in the study who were less than 40 years of 
age; of these, 14% had primary ovarian failure.
Cochrane and Regan (1997) found 53 of the 100 women 
required contraception; 13 of these had never had 
contraceptive counseling. An intrauterine device was found 
in 5 patients, which is not recommended for these patients 
as it may exacerbate menorrhagia and increase the risk of 
infection in immunosuppressed women. There also were 24 
women identified who could potentially become pregnant; of 
these, 92% had involuntary infertility.
Only 2 women were originally referred for an abnormal 
cervical smear. After initial examination of all subjects,
8 more were identified to have an abnormal cervical smear.
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Of these women, 4 were diagnosed by colposcopy with 
cervical intraepithélial neoplasia (CIN), and 1 was found 
to have invasive cervical carcinoma and underwent 
hysterectomy.
Prolactin levels in all subjects were normal except 
for those on hemodialysis, which were elevated. The 
researchers concluded that 85% of these patients had 
menstrual disorders, mainly menorrhagia, which was of 
concern because heavy vaginal bleeding worsens the anemia 
of CRF and may necessitate blood transfusion. Transfusions 
are undesirable as they cause atypical and cytotoxic 
antibodies which decreases the chance of successful organ 
matching. Also, treatment with erythropoetin is expensive 
and may be withheld in women with persistent menorrhagia. 
For treatment of menorrhagia, the researchers supported 
the use of high-dose medroxyprogesterone acetate 
(Provera).
Cochrane and Regan (1997) concluded that menstrual 
disorders were not reduced after renal transplantation, 
and approximately 33 subjects were amenorrheic. This 
menstrual disorder was not perceived to be a problem by 
the nephrologists. Of the 35 women identified as 
menopausal, all were recommended and encouraged to 
initiate HRT. The researchers cited these patients to be 
at high risk for osteoporosis because of the cumulative
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effects of ovarial failure, long-term steroid therapy, and 
CRF. Cochrane and Regan also found that contraceptive 
counseling had been inappropriate or nonexistent, and they 
recommended all women with CRF seek contraceptive 
counseling. Low-dose combined oral contraceptives were 
recommended for most patients and had the added benefit of 
improved cyclic control. Severe hypertension and active 
systemic lupus were cited as contraindications to oral 
contraceptive. The researchers also identified an 
eightfold increase in cervical dyskariosis and related 
this to the use of immunosuppressive drugs. Of 
significance is the fact that 80% of these abnormalities 
would have been missed had the researchers not preformed 
cervical smears on all patients. Therefore, these 
researchers recommended that women with CRF on 
immunosuppressive therapy undergo annual cervical 
screening.
Cochrane and Regan (1997) confirmed the value of 
regular gynecological surveillance for seemingly 
asymptomatic women with chronic renal failure based on the 
unrecognized pathology identified in the study. This 
current researcher finds this study applicable to her 
study because of the high incidence of undetected 
gynecological disorders in this population of patients.
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These disorders could potentially complicate and aggravate 
the management of renal disease.
Of interest to the researcher were patient profiles 
of current HRT use. Therefore, studies that included 
demographic and clinical data of patients who were 
prescribed HRT were reviewed.
In 1999, Gillen, Gipson, and Stehman-Breen conducted 
a secondary analysis of data from the United States Renal 
Data Systems (USRDS) Dialysis Morbidity and Mortality 
Study (DMMS) Wave 2. They sought to assess the prevalence 
and predictors of HRT in postmenopausal women with ESRD.
The DMMS had detailed demographic, behavioral, and 
medical history of patients with ESRD. This prospective 
study included a random sample of patients from 25% of the 
dialysis facilities in the United States that opened after 
January 1, 1994. The subjects were at least 18 years of 
age, had been on dialysis for more than 90 days, and 
qualified for Medicare. Subjects who were previously 
transplanted and or were on home dialysis were excluded 
from the study. Data were collected by dialysis facility 
personnel. Patient demographic and behavior data obtained 
were gender, age, race, weight, height, marital, 
employment, and educational status. Clinical data included 
medications, co-morbid conditions, and exercise frequency.
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Of the DMMS sample, Gillen et al. selected 1,499 
subjects for the secondary analysis. All females age 45 
and older were considered postmenopausal and included in 
the study. From the medication list, the use of estrogen, 
progesterone, or a combination was determined for each 
subject. The use of HRT among the subjects was predicted, 
utilizing logistic regression to estimate the independent 
contribution of demographic, behavioral, and medical 
history variables. The odds ratios were interpretable as 
the adjusted odds of being prescribed HRT for each 
variable of interest. Confidence intervals were 
established using the estimated standard error of the 
coefficient (Bl) from the logistic regression analysis.
The relationship between HRT and triglycerides and 
cholesterol were estimated using linear regression and 
reported as the mean difference in triglyceride or 
cholesterol between subjects who used HRT and those who 
did not, along with 95% confidence intervals. SPSS 
statistical software was used to analyze the data.
Gillen et al. (1999) determined the prevalence of HRT 
prescription among the subjects was 10.8% (162 out of 
1,499). Prescription prevalence was highest in the fifth 
decade of life (18%) and lowest in the eighth decade (7%). 
Women in their 4 0s received HRT 15% of the time, while 
those in their 60s and 70s had a prevalence of 8%.
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Ninety-five percent of the subjects were prescribed 
estrogen and or progesterone separately, whereas the 
remaining subjects (n = 8) were prescribed a combination 
preparation. For each decade of life, subjects were 2 6% 
less likely to be prescribed HRT. This was compared to a 
previous study which cited HRT use in the general 
population which was 34%.
The researchers determined predictors of HRT use 
among the subjects, including age, ethnicity, education, 
and ambulation status. All predictions were made after 
adjusting for education, race, and independent ambulation. 
Black subjects were 50% less likely to be prescribed, HRT 
than white subjects (aOR=0.50, p < .002). Subjects with a 
college degree were threefold more likely to be prescribed 
HRT than those with a high school degree or less 
(aOR=2.98, p < .001). Ambulatory women were nearly twofold 
more likely to be prescribed HRT than those who were not 
ambulatory (aOR=l.99, p = .05). In addition, subjects with 
diabetes were less likely to be prescribed HRT than 
nondiabetics (OR=0.65, p < .01). Cholesterol levels were
11.0 mg/dl (95% Cl, 1.5 to 20.5) higher in subjects 
prescribed HRT compared to women not on HRT. Triglyceride 
levels were 47.2 mg/dl (95% Cl, 18.9 to 75.5) points 
higher in women using HRT.
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Gillen et al. (1999) cited factors which might 
explain the overall low rate of HRT prescription in 
postmenopausal women with ESRD, including physician 
attitude, ethnicity, secular trends, and geographic 
location. Also, variation in demographic distribution 
between women with and without ESRD could account for much 
of the difference in the rate of HRT prescription.
The researchers concluded that HRT use in the general 
population is greater than in women with ESRD. The most 
important predictors of HRT prescription in postmenopausal 
women with ESRD were younger age, higher education. White 
race, and ambulatory status. The current researcher finds 
this study applicable to her study and agrees with the 
researchers that targeting groups of women who are likely 
to benefit from, but least likely to be prescribed, HRT 
could increase the prescriptions of HRT in this 
population.
A study of women with ESRD to identify menstrual 
patterns, contraception, HRT use, and sexuality issues was 
conducted by Holley, Schmidt, Bender, Dulmer, and Schiff 
(1997). The sample was 191 women receiving hemodialysis at 
four dialysis facilities in the United States. Inclusion 
criterion was women less than 55 years old when they began 
dialysis. Medications were reviewed for estrogen 
replacement only. Women less than 55 years of age
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completed the questionnaire (N = 76), and their responses 
formed the data for the study. Women older than 55 were 
excluded from the study (n = 115) and only completed part 
of the questionnaire. The demographic data on the 
questionnaire included age, race, mode of dialysis, age at 
start of and time on dialysis, and use of recombinant 
erythropoietin. Also included on the survey were questions 
concerning pregnancies, menstrual cycle, sexual activity, 
use of birth control pills and HRT, and questions 
concerning preventative health care. Of these subjects, 52 
were on hemodialysis, and 24 were on peritoneal dialysis.
Statistical analysis utilized the chi-square test for 
comparison of proportions. In addition, the Mann-Whitney Ü 
test and student t test were used when appropriate. Data 
were represented as mean values + standard deviation or 
medians, and £ < .05 was considered significant.
Of the 7 6 subjects in the study group, 70% (n = 53) 
had been pregnant at least once; 4 (2%) of the pregnancies 
occurred after dialysis was initiated. Of the 4 subjects 
who became pregnant while on dialysis, only 2 reported 
birth control discussions by their nephrologists or 
primary health care provider, and 1 continued to be 
sexually active without using birth control. The response 
of subjects on hemodialysis (n = 52) and peritoneal 
dialysis (n = 24) were summed and analyzed together as
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there was no significant difference in the responses 
between groups. Holley et al. found that 32 of the 
subjects were currently menstruating; of those, 59% (n = 
19) reported irregular menses. The sample reported heavy 
flow with clots when compared with flow before starting 
dialysis (14 of 22 [64%] vs. 18 of 48 [38%]: £ = .05). Of 
the study subjects, 19 (n = 28) were postmenopausal; of 
these, 5 reported menopause occurring after starting 
dialysis. Although the median age of the subjects was 43, 
only 50% reported being sexually active; postmenopausal 
women were less likely to be sexually active (4 of 17 vs.
30 of 49; £ = .01). Of these sexually active women, 36% (n 
= 27) reported using birth control. Only 13% (n = 9) 
reported discussing birth control options with their 
nephrologists. Of the sample, 63% (n = 47) had yearly 
papanicolaous smear, and 73% (n = 50) had a mammogram.
Of the study subjects, 19 (28%) were postmenopausal; 
53% (n = 10) reported experiencing menopause naturally. 
Only one of the postmenopausal women received estrogen 
replacement therapy, the remainder either did not answer 
the question or were not using any form of HRT. Of the 20 
subjects who did not answer the question concerning HRT 
(24 of 44), Holley et al. determined through a review of 
the medication list that 5% were on estrogen replacement
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therapy. Of 113 subjects 55 and older, only 5% were 
receiving estrogen replacement therapy.
Holley et al. (1997) concluded that 42% (n = 32) of 
the subjects were currently menstruating, which contrasts 
with earlier researchers who determined 10% of 
premenopausal women on dialysis had regular menses. Holley 
et al. established that the use of recombinant 
erythropoietin contributes to the significant increase in 
menses in these subjects. Ureamic women have an acyclic 
pattern of gonadotropin release because of impaired 
estradiol stimulation, which possibly is related to 
hyperprolactimemia. In addition, high prolactin levels 
were postulated to be contributory to decreased libido and 
lower frequency of sexual intercourse among females with 
ESRD. The researchers also concluded that some features of 
contemporary dialysis care, such as the use of recombinant 
erythropoietin with improved hematocrits and adequacy of 
dialysis, may be related to reduced prolactin levels.
The current researcher finds the overall low rate of 
hormone prescription in Holley et al.'s sample of 
postmenopausal women is a concept of this current study. 
Also, of particular interest was the low incidence of 
counseling to premenopausal women by their nephrologists 
or primary health care provider. Holley et al. recommended
4 1
further study to validate their findings and determine why 
the rates of HRT were so low.
Lyhne and Pedersen (1995) conducted a 2-year 
prospective study of 23 dialysis patients at Odense 
University Hospital in Denmark. The purpose of the study 
was to evaluate the medical treatment of renal 
osteodystrophy, a condition found frequently in patients 
with ESRD. The subjects included 12 women and 11 men. 
Median age for females was 54 (range 27 to 68) and 60 for 
men (range 24 to 68). Inclusion criteria were initiation 
of dialysis between 1985 and 1990, peritoneal dialysis as 
first mode of dialysis, and less than a 2-month 
interruption in treatment. Exclusion criteria were 
previous use of steroids, oestrogen in any form, or 
hormonal contraceptives. The cause of renal failure was 
equally distributed between male and female subjects and 
primarily included glomerulonephritis, diabetic 
nephropathy, and polycystic kidney disease.
At baseline and every 6 months during the study, bone 
mineral content was measured by single photon 
absorptiometry at the fixed radius of the dominant 
forearm. The mean value was calculated by the average of 
four 2-dimensional scans. This method has an accuracy of
0.958 (the coefficient of correlation between bone mineral 
content and bone calcium content) and 0.8 - 1.4%
42
reproducibility. In addition, serum 1,25 (OH) 2 D3 levels 
were measured at the beginning of the study and every 6 
months. Baseline and monthly serum total calcium, albumin, 
phosphate, total alkaline phosphate, and bicarbonate 
levels were also measured (Lyhne & Pedersen, 1995).
Daily treatment modality included four dialysis 
exchanges per day, using Ca++ 3.5 mEq/L dialysate bags, 
oral phosphate binder, and oral Vitamin D3 (l-alpha-0H-D3) 
supplementation. The median dose of Vitamin D3 over the 
24-month study period was 0.25 for both males and females. 
The mg/kg median dose of phosphate binder for both genders 
during the study was 12. Serum 1,25 (OH) 2D3 levels and 
bone mineral content were not taken into account when 
prescribing doses.
Lyhne and Pedersen (1995) utilized Wilcoxon's test of 
paired data and Mann-Whitney's test of unpaired data to 
evaluate results. Ranges or medians were used to describe 
results, with calculations of the p and 95% confidence 
limits of the median. Kendall's rank test was used for 
correlation tests. The bone mineral content was expressed 
in percentage of the initial value.
The researchers determined that the bone mineral 
content significantly decreased (p < .001) for female 
subjects over the 24-month study period when compared to 
male subjects. The median decrease of bone mineral content
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for females was 12% over 2 years, but was nonsignificant 
for males subjects (p < .01). No significant correlation 
emerged between age and bone mineral content change in 
either group (Kendall's T = 0.182 and 0.067, 
respectively). (Comparative findings in the general 
population has shown bone mineral content decreases of 1% 
per year in females ages 35 to 65 years and a 2% decrease 
during perimenopause.) The researchers found no 
significant difference in oral vitamin D3 dose or serum D3 
levels in either group. Female subjects demonstrated a 
significant increase in serum Ca++ (p < .05), as well as a 
decrease in serum phosphate (p < .05), while male subjects 
showed no significant change in either. However, there was 
a significant decrease in serum albumin and body weight in 
the male group (p < .01 and p < .05, respectively), but 
only slight decreases in the serum albumin and maintenance 
of body weights (100% of weight at start vs. 105% at 24 
months) in the female group.
Lyhne and Pedersen (1995) concluded that the women 
who had peritoneal dialysis as first mode demonstrated a 
significant decrease in bone mineral content as compared 
to men, even though lab values and maintenance of body 
weight demonstrated better treatment outcomes in the 
female groups. The researchers also concluded that this 
significant decrease compared to the general population
4 4
suggest severe skeletal imbalances in the female subject 
group which could indicate a sex hormone-related 
disturbance.
Summary
There were no empirical studies in the review of 
literature that specifically identified barriers and 
facilitators to HRT initiation; however, there were 
numerous studies that cited the benefits to correction of 
estrogen deficiency among postmenopausal women with renal 
failure.
Several previous studies have examined reproductive 
and sexuality issues among women with renal failure. 
Matuszkiewicz-Rowinska et al. (1999) conducted a study of 
23 postmenopausal women with renal failure to evaluate the 
effect of HRT on sexual function, estrogen and prolactin 
levels, and bone mineral density. The researchers 
concluded that normalization of estradiol levels in these 
women with previous oestradiol deficiency is sufficient to 
prevent bone loss, increase bone formation, and improve 
libido. Cochrane and Regan (1997) undertook a prospective 
study which aimed to establish the nature and extent of 
gynecological disorders among 100 women with ESRD and or 
who had received a renal transplant. The researchers found 
that reproductive problems were frequent and unrecognized
4 5
and menopausal symptoms were undertreated. Of the 
subjects, 58% had a menstrual disorder, with uncontrolled 
menorrhagia being a significant problem and 45% were found 
to be postmenopausal. The researchers determined that 80% 
of the abnormalities identified would have been missed had 
they not performed cervical smears on all patients. In 
another study of women receiving dialysis, Holley et al. 
(1997) identified sexuality issues, menstrual patterns, 
contraception, and HRT use. The researchers reported the 
median age for menopause was 47 years, and only one 
postmenopausal woman received HRT.
The study conducted by Lyhne and Pedersen (1995) to 
evaluate the treatment of renal osteodystrophy found a 
significant decrease in bone mineral content in women as 
compared to men. The researchers concluded that women who 
had peritoneal dialysis as first mode demonstrated a 
significant decrease in bone mineral content as compared 
to men even though lab values and body weight demonstrated 
better treatment outcomes in the female groups. Lyhne and 
Pedersen also concluded that the significant decrease in 
bone mineral content of females on dialysis suggest severe 
skeletal imbalances which could indicate a sex hormone 
related disturbance.
Few studies have specifically addressed current HRT 
prescription. In 1999, Gillen et al. conducted a secondary
4 6
analysis of 1,499 females ages 45 and older and on 
dialysis using data from the United States Renal Data 
Systems (USRDS) Dialysis Morbidity and Mortality Study 
(DMMS) Wave 2. They sought to assess the prevalence and 
predictors of HRT in postmenopausal women with ESRD.
Gillen et al. (1999) determined the prevalence of HRT 
prescription among the subjects was 10.8% (162 out of 
1,499); and for each decade of life, subjects were 26% 
less likely to be prescribed HRT. Gillen et al. (1999) 
cited factors which might explain the overall low rate of 
HRT prescription in postmenopausal women with ESRD, 
including physician attitude, ethnicity, secular trends, 
and geographic location. The most important predictors of 
HRT prescription in postmenopausal women with ESRD found 
by their researchers were younger age, higher education, 
white race, and ambulatory status.
Recent studies have documented a significant decrease 
in CVD mortality among women who received HRT. Ginsburg et 
al. (1998) conducted a study of women ages 45 years and 
older with renal failure to examine the effects of 
estrogen therapy on lipoproteins. The researchers found a 
20% increase in HDL after only 4 weeks of oral estradiol 1 
mg. Previous studies in patients with no renal failure 
have suggested that comparable increases in HDL are 
expected to decrease the risk of CVD by 50%. Many
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treatments for hyperlipidemia in the ESRD population have 
been evaluated, including gemfibrozil, probucol, 
lovastatin, and simvastatin. Many of these lipid-lowering 
agents have major side effects, such as rhabdomyolysis and 
elevated hepatic transaminases. The researchers concluded 
that similar benefit from estrogen replacement therapy may 
be achieved with fewer side effects, and they advocated 
the use of 1 mg estradiol for future trials to minimize 
the risks associated with higher hormone levels.
In conclusion, the review of literature supported the 
current study which found that approximately 10% of 
postmenopausal women receive HRT. The literature review 
also supported the need for more research concerning 
menopause among women with ESRD.
Chapter III 
The Method
This researcher sought to identify the barriers and 
facilitators to nephrology health care providers 
initiating hormone replacement therapy (HRT) in 
postmenopausal women with end-stage renal disease (ESRD). 
Nephrology health care providers in Alabama, Mississippi, 
and Tennessee were surveyed utilizing a researcher- 
developed tool, Tramel's Questionnaire, to identify 
current HRT prescribing practices. An open-ended question 
was provided for additional information. Included in this 
chapter are study design, setting, population and sample, 
instrumentation, procedures, and data analysis.
Design of the Study
A descriptive study design was used since the 
researcher sought to explore and document aspects of a 
setting as it occurs naturally (Polit & Hungler, 1999). 
The aim of this descriptive study was to identify the 
barriers and motivators to nephrology health care 
providers initiating HRT in their postmenopausal clients.
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Setting, Population, and Sample
The setting for this study was outpatient 
hemodialysis facilities in Alabama, Mississippi, and 
Tennessee. The total number of dialysis facilities in 
these three states is approximately 300. The patient 
census for each unit varies from 10 to 100 patients. 
Currently, there are approximately 15,000 ESRD patients 
receiving dialysis at these facilities. The target 
population was nephrology health care providers in 
Alabama, Mississippi, and Tennessee who care for 
postmenopausal women aged 45 years or older who have had 
ESRD for more than 6 months. There are an estimated 200 
nephrologists in the tri-state region (T. Wooldridge, MD, 
personal communication. May 8, 2001). The target sample 
consisted of 100 subjects who met criteria and completed 
and returned the questionnaire. The actual sampling was 26 
which represents a 17% return.
Instrumentation
Tramel's Questionnaire, a researcher-developed 
instrument, was utilized to collect data concerning 
demographic and descriptive practices of nephrology health 
care providers in Alabama, Mississippi, and Tennessee 
regarding HRT in their postmenopausal women with ESRD. The 
instrument is assumed to face validity within the confines
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of this study as it was reviewed by a panel of research 
experts and piloted for clarity by a health care provider 
in nephrology. Since there is no summative score, 
questions were analyzed independent of each other.
Procedures
Prior to implementation of this study, permission was 
obtained from the Mississippi University for Women 
Committee on Use of Human Subjects in Experimentation (see 
Appendix A ) . ESRD facilities addresses were obtained from 
Network 8, a Health Care Financing Committee (HCFA), data 
collection agency. Ten dialysis facilities in Alabama, 
Mississippi, and Tennessee were each sent a packet of five 
of the following : Trame 1's Questionnaire (see Appendix B), 
cover letter with information about the study (see 
Appendix C), and a stamped, self-addressed return 
envelope. A follow-up postcard was mailed to the dialysis 
facilities 2 weeks later (see Appendix D). This approach 
only stimulated five returns. A telephone conference of 
research committee members was set up to choose an 
alternative data collection method. The committee decided 
that personal contact per telephone with nephrology health 
care providers was appropriate. Thirty nephrologists were 
contacted in Alabama, Mississippi, and Tennessee; packets 
were faxed to the care provider with the same information
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that was originally sent (see Appendix E). Employing both 
methods of data collection, a final sample of 26 (17% 
return) was achieved. Confidentiality was maintained as no 
survey had any identifying data. Return of the 
questionnaire indicated the subject's consent to 
participate. Data collection took place during the months 
of April and May 2001.
Data Analysis
Questions 1 and 2 are demographic questions and 
require a check (^) only response. Questions 3, 4, 5, and 
6 deal with patient load and require either a check (/) or 
fill-in-the-blank response. Descriptive statistics 
including frequency distribution, percentages, and means 
were utilized to analyze these questions. Questions 7, 8, 
and 9 concern barriers and facilitators to HRT initiation 
and required the health care provider to rank five 
responses in order of importance: 1 (the most prevalent) 
and 5 (the least prevalent). Question 10 was an open-ended 
question and prompted the nephrology health care provider 
to write comments relevant to the research study. Only 
four responses were received for Question 10. Content 
analysis was used to identify themes; facilitators and 
barriers to HRT initiation were discussed in the open- 
ended question. Among the comments were the need for more
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research, lack of educational opportunities, and inability 
to monitor the patient if prescribed HRT.
Summary
The purpose of this study was to describe 
facilitators and barriers to initiation of HRT by 
nephrology health care providers among postmenopausal 
women with ESRD. A researcher-developed questionnaire. 
Trame1's Questionnaire, was used to collect data. 
Descriptive statistics, including ranking, frequency 
distribution and percentages, were utilized to analyze the 
data.
Chapter III described empiricalization of the study. 
Chapter IV will discuss the findings, and Chapter V will 
describe the outcomes of the study.
Chapter IV 
The Findings
The purpose of this descriptive, nonexperimental 
study was to identify the factors that influence 
nephrology health care providers to prescribe hormone 
replacement therapy (HRT) for postmenopausal women under 
their care. The research questions that guided this study 
were as follows :
1. What are the facilitators cited by nephrology 
health care providers to initiate HRT for postmenopausal 
women with end-stage renal disease?
2. What are the barriers cited by nephrology health 
care providers to initiate HRT for postmenopausal women 
with end-stage renal disease?
Within Chapter IV, a detailed description of the 
sample, results of data analysis, and additional findings 
are presented.
Description of the Sample
One hundred fifty researcher-developed questionnaires 
were mailed to nephrology health care providers in
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Alabama, Mississippi, and Tennessee. Twenty-six 
questionnaires (17%) were returned. The convenience sample 
consisted of nephrology health care providers who cared 
for women, ages 47 years and older, who had renal failure 
for more than 6 months. Twenty-three (88.4 6%) of the 
subjects were board-certified in nephrology, 1 (3.85%) was 
a medical doctor, and 2 (7.69%) were nurse practitioners. 
The sample represented three states: Alabama 2 6.92 (n =
7), Mississippi, 52.31% (n = 11), and Tennessee 26.92% (n 
= 7). The average number of years practicing as a health 
care provider was 12.8 years, and the majority (88.77%) of 
the sample were male. Questions regarding patient 
population also were included. The majority (26.92%) 
currently provided care for 301 to 400 ESRD patients ; the 
current range for patients seen was 101 to 700. Subjects 
reported caring for an average of 138 female patients who 
met inclusion criteria. Eleven (42.31%) of the male health 
care providers identified that 6% to 10% of their eligible 
postmenopausal women were receiving HRT, while the 2 
female health care providers identified that > 50% (7.6%)
of their eligible women patients were on HRT. Nephrology 
health care providers were asked how many continuing 
education units (CEUs) they have received regarding HRT or 
menopause. An overwhelming 7 6.92% (n = 20) reported having 
received no CEUs during the past year; 23.08% (n = 6)
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reported 1 to 5 CEUs. Only 12 (46.15%) reported CEUs in 
the last 5 years and 10 (38.46%) still reported no CEUs.
Results of Data Analysis
The researcher sought to identify facilitators and 
barriers to initiation of HRT among postmenopausal women 
with renal failure. The first research question was as 
follows: What are the facilitators cited by nephrology 
health care providers to initiation of HRT among 
postmenopausal women with ESRD? Questions 7 and 9 on 
Tramel's Questionnaire concerned facilitators. For 
Question 7 the care provider ranked, in order of 
importance, reasons they would initiate HRT among their 
postmenopausal patients. The majority ranked surgically- 
induced menopause as the number one reason to initiate 
HRT, and all respondents ranked cardiovascular disease 
(CVD) protection as the least likely reason to initiate 




Health Facilitators to HRT Initiation by Nephrology Health 
Care Providers Using Rank Order by Question
Question State® Rank
7. Reasons you would initiate 
HRT in postmenopausal women 
under your care:
Surgically-induced menopause AL 1
Patients ask for it AL 2
Relief of menopausal symptoms AL 3
Prevention of osteoporosis AL 4
Cardiovascular disease protection AL 5
Surgically-induced menopause MS 1
Patients ask for it MS 2
Relief of menopausal symptoms MS 3
Prevention of osteoporosis MS 4
Cardiovascular disease protection MS 5
Surgically-induced menopause TN 1
Relief of menopausal symptoms TN 2
Patients ask for it TN 3
Prevention of osteoporosis TN 4
Cardiovascular disease protection TN 5
Note. AL = Alabama. MS - Mississippi, TN = Tennessee. 
^Alabama (n = 7), Mississippi (n = 11), Tennessee (n = 7)
For Question 9 care providers ranked factors that 
would make it easier or more convenient to prescribe HRT. 
The majority ranked the need for more research prior to 
their initiating HRT as number one. The development of a 
pocket guide was considered last as a facilitator by all
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respondents. These factors are considered external 
facilitators and are listed in Table 2.
Table 2
External Facilitators to HRT Initiation by Nephrology 
Health Care Providers Using Rank Order by Question
Question State® Rank
9. What would make it easier or more 
convenient for you to prescribe HRT?
Journal articles AL 1
More research AL 2
Presentations AL 3
Continuing education units (CEUs) AL 4
Pocket guide AL 5
More research MS 1
Presentations MS 2
Journal articles MS 3
Continuing education units (CEUs) MS 4
Pocket guide MS 5
More research TN 1
Presentations TN 2
Journal articles TN 3
Continuing education units (CEUs) TN 4
Pocket guide TN 5
Note. AL = Alabama. MS = Mississippi, TN = Tennessee
^Alabama (n = 7), Mississippi (n = 11), Tennessee (n == 7) .
The second research question was as follows: What are 
the barriers to initiation of HRT among postmenopausal 
women with ESRD? For Question 8 nephrology health care
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providers ranked, in order of importance, reasons they 
would not initiate HRT. The majority ranked physician 
liability as the number one reason they would not initiate 
HRT and ranked CVD as the least important reason they 
would not initiate HRT (see Table 3).
Table 3
Barriers to HRT Initiation by Nephrology Health Care 
Providers Using Rank Order by Question
Question State® Rank
8. Reasons you would not initiate 
HRT in postmenopausal women 
under your care
MD liability AL 1
Unsure of type and dose to prescribe AL 2
View as primary care/gyn AL 3
Concerns of adverse effects AL 4
Preexisting cardiovascular disease AL 5
View as primary care/gyn MS 1
MD liability MS 2
Preexisting cardiovascular disease MS 3
Concerns of adverse effects MS 4
Unsure of type and dose to prescribe MS 5
8. Reasons you would not initiate 
HRT in postmenopausal women 
under your care
MD liability TN 1
View as primary care/gyn TN 2
Concerns of advert effects TN 3
Preexisting cardiovascular disease TN 4
Unsure of type and dose to prescribe TN 5
Note. AL = Alabama. MS = Mississippi, TN = Tennessee. 
®Alabama (n = 7), Mississippi (n = 11), Tennessee (n = 7)
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Only 4 subjects responded to Question 10 on Tramel's 
Questionnaire. This open-ended question allowed for 
comments relevant to this study. There was no emergent 
theme. However, the researcher took the liberty of 
classifying responses as either facilitators or barriers.
Facilitators
I would definitely like to see more research
concerning HRT in our patient population.
[External facilitator)
Presentations, especially for nurse 
practitioners in nephrology, would be helpful.
Barriers
I am based in an acute care setting and not 
directly involved in prescribing routine 
medications and would not have the opportunity 
to monitor the patient in this setting.
I feel that nurse practitioners practicing in 
nephrology do not have enough educational 
opportunities specifically addressing the ESRD 
patient on the local level.
Coverage and financial issues are barriers to 
attending national meetings.
Limitations
The researcher identified the following potential 
limitations for this study. A sample bias due to limited 
geographic setting and small sample size could have been
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present which would prevent generalization of the results. 
However, due to limited time and financial support, the 
researcher made efforts to include at least representation 
from three states. Opportunity to participate was provided 
for 150 prospective nephrology health care provider.
There were some methodological constraints. The 
researcher-developed instrument had no validity 
established and may not have represented all facilitators 
or barriers for choice. However, the researcher did 
identify potential facilitators and barriers to HRT 
prescription from the review of literature. Further, the 
questions were reviewed by a nephrology health care 
provider and a research committee of experts. The 
instrument was assured to have face validity within 
confines of this study. Another methodology concern to 
this researcher was the subject recruitment process. The 
mailed survey process failed as it only stimulated five 
respondents, personal contact by phone was then made with 
45 nephrology health care providers. This second process 
stimulated 21 respondents. These subjects may have 
responded to please the researcher.
Summary
The purpose of this study was to describe 
facilitators and barriers to initiation of HRT among
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postmenopausal women with ESRD. Analysis of responses 
recorded on Tramel's Questionnaire regarding these factors 
was described in this chapter. The sample consisted of 26 
nephrology health care providers who currently practice 
and care for ESRD patients in Alabama, Mississippi, and 
Tennessee. Only two respondents were nurse practitioners. 
Descriptive statistics, including frequency distribution, 
percentage and ranking, were utilized to analyze the data. 
Nephrology health care providers were 80.77% (n = 21) male 
and practiced nephrology for an average 12.8 years. The 
average number of postmenopausal women under their care 
was 138 while 42.31% (n = 11) reported prescribing HRT for 
these women. Tramel's Questionnaire reported an 
overwhelming 76.92% (n = 20) received no CEUs during the 
past year while only one to five CEUs were reported during 
the last 5 years by the majority of nephrology health care 
providers (42.31%, n = 12). Health facilitators ranked as 
number one were surgically-induced menopausal. External 
facilitators that ranked as number one was the need for 
more research in the area of HRT for women with renal 
failure. The number one ranked barrier to HRT initiation 
was concerns of physician liability.
Chapter V 
The Outcomes
The population of postmenopausal women in the United 
States is increasing at an exponential rate. In 1990 there 
were 28.7 million women older than 55 years of age; by the 
year 2020 this group is estimated to be 45.9 million. In 
1999 over 31 million women began the menopausal transition 
(Lobo, 1999). As the general population ages, the number 
of postmenopausal women with end-stage renal disease 
(ESRD) also will increase. The prevalence rate for ESRD 
among postmenopausal women was 607 per million in 1991 and 
had climbed to 931 per million in 1997 (Mattix & Singh,
2000). Cardiovascular disease (CVD), osteoporosis, and 
dementia are three disease processes that profoundly 
affect the quality of life and health of ESRD patients who 
are menopausal (D. Arnold, personal communication. May 14,
2001).
Nephrology health care providers have ignored the 
issue of hormone replacement therapy (HRT) in their 
postmenopausal patients despite mounting evidence that 
estrogen therapy could possibly decrease morbidity and
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mortality and positively influence quality of life (Mattix 
& Singh, 2000). In an effort to better understand the 
disparity of HRT prescription in women with ESRD, this 
researcher explored the prescription practices of 
nephrology health care providers regarding initiation of 
HRT. The research questions that guided this study were as 
follows :
1. What are the barriers cited by nephrology health 
care providers to initiate HRT for postmenopausal women 
with end-stage renal disease?
2. What are the facilitators cited by nephrology 
health care providers to initiate HRT for postmenopausal 
women with end-stage renal disease?
Pender's Health Promotion Model was the theoretical 
framework used to guide this study. Within this chapter 
the outcomes, implications, and recommendations that 
evolved from this study are presented.
Description of the Sample
A convenience sample of 26 nephrology health care 
providers who care for women, are at least age 47 years 
old, and have had renal failure for more than 6 months.
The majority (88.46%) of the nephrology health care 
providers were board certified in nephrology, were 
practicing in Mississippi (52.31%), and were male
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(88.77%) . The average number of years practicing as a 
health care provider was 12.8 years. Questions regarding 
patient population also were included on the 
questionnaire. The majority (26.92%) are health care 
providers for 301 to 400 ESRD patients; the range for 
patients seen was 101 to 700. Nephrology health care 
providers reported caring for an average of 138 female 
patients age 47 and older, and the majority (42.31%, n = 
11) reported 6-10% of these women currently received HRT. 
The researcher sought to determine the number of 
continuing education units (CEUs) care providers had 
received regarding HRT or menopause. An overwhelming 
76.92% (n = 20) reported having received no CEUs during 
the past year.
Summary of Significant Findings
The research questions that guided this study were as 
follows :
1. What are the barriers cited by nephrology health 
care providers to initiate HRT for postmenopausal women 
with end-stage renal disease?
2. What are the facilitators cited by nephrology 
health care providers to initiate HRT for postmenopausal 
women with end-stage renal disease?
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Using a ranking format the number one health 
facilitator cited by nephrology health care providers to 
initiate HRT was surgically-induced menopause, and the 
number one reported external reason nephrology health care 
providers would initiate HRT was more research to validate 
benefits verses adverse effects within this population of 
patients. The most ranked barrier for the nephrology 
health care providers to initiate HRT was concern of 
liability.
Discussion Related to Findings
Since there were no empirical studies that 
specifically dealt with barriers and facilitators to 
prescribing HRT, the findings of this research can neither 
be supported nor refuted. Of particular interest to the 
current researcher were established facilitators of HRT 
such as the prevention of osteoporosis, CVD, dementia, and 
quality-of-life improvement in women eligible for HRT who 
have renal failure. Clinical evidence to support the use 
of HRT as primary prevention clearly exists; however, 
nephrology health care providers seem to ignore this 
treatment and opt not to prescribe HRT to their 
postmenopausal patients. There was support found 
establishing the preventative benefits of HRT by 
Matuszkiewicz-Rowinska et al. (1999) who concluded that
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normalization of serum oestradiol levels with use of HRT 
is sufficient to prevent bone loss and increase bone 
formation. Nephrology health care providers in this 
current study ranked that response as number four in order 
of importance for initiating HRT.
Consideration of HRT as a preventive action for CVD 
was confirmed by Mattix and Singer (2000). These 
researchers concluded that CVD in patients with renal 
failure had reached epidemic proportions and that 42% of 
all deaths in women age 45 to 64 years was due to CVD. 
Ginsburg et al. (1998) also contributed to the position of 
HRT as a preventive treatment when they determined that 
oral estradiol increases total HDL. Previous studies in 
patients with no renal failure have suggested that 
comparative increases in HDL are expected to decrease the 
risks of CVD by 50%. For the current study, subject 
responses did not support the concern for prevention of 
CVD as they ranked that response as number five, or last 
in order of importance on Question 7.
There were concerns in Ginsberg et al.'s (1998) study 
about side effects of estrogen replacement therapy among 
women with renal failure. Question 8 addressed this issue. 
When the subjects ranked reasons they would not initiate 
HRT, they chose concerns of adverse effects of HRT as
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number three of five, which does not support Ginsburg et 
al's position.
Matuszkiewicz-Rowinska et al. (1999) discovered a 
substantial improvement in sexual function, mood, and 
mental alertness, and an improvement in general well­
being, factors that have a significant role in quality of 
life. Relief of symptoms of menopause as a response, which 
would contribute to quality of life, was identified as a 
selection to initiate HRT. Care providers ranked this as 
number three. Also, "patients ask for it" was the number 
two response which somewhat supports Matuszkiewicz- 
Rowinska et al. (1999) research for when patients ask for 
HRT there is an implied need to feel better.
Gynecological surveillance is important to all women 
with ESRD. Cochrane and Regan (1997) confirmed the value 
of gynecological surveillance in that 80% of abnormalities 
found in their subjects would have been missed had the 
researchers not performed cervical smears on all patients. 
Cochrane and Regan also found 53 of the 100 women required 
contraception and that counseling in this regard had been 
inappropriate or nonexistent. The current study results 
support the need for gynecological surveillance as the 
average number of female patients age 47 and older seen by 
the nephrology health care provider was 138 representing 
42% of all their patient.
68
Eleven (42.31%) of the male health care providers 
identified that 6-10% of their eligible postmenopausal 
women were receiving HRT, while the two female health care 
providers identified that > 50% (7.6%) of their eligible 
female patients were on HRT. This finding supports the 
Health Promotion Model in that modifying factors, such as 
gender, race, and age, directly influence health-promoting 
behaviors.
Gillen et al. (1999) cited factors which might 
explain the overall low rate of HRT prescription in 
postmenopausal women with ESRD. These researchers 
suggested that physicians' attitudes, ethnicity, secular 
trends, and geographical location may have impacted the 
prescribing patterns of these nephrology health care 
providers. The current study's subjects in these 
southeastern states were predominantly male (80.77%) with 
a general lack of knowledge regarding women's health as 
evidenced by their response of uncertainty of dose to 
prescribe HRT. While ethnicity or secular trends were not 
identified in the current study, it is possible that the 
southeastern geographical location could have influenced 
these nephrology health care providers. Physician 
liability was ranked as the number one reason for not 
prescribing HRT. This factor either indicates true lack of 
knowledge in regards to HRT or that HRT is viewed by the
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sample as an area for treatment solely ascribed to the 
primary care provider. Another interpretation might be 
that nephrology health care provider's are simply not 
interested in women's health issues for they answered a 
lack of interest in both continuing education units 
related to HRT and no desire to possess an HRT pocket 
guideline. The need for increased knowledge may be masked 
or denied by the provider as exhibited in Question 8 when 
physician liability was chosen as the reason they would 
not initiate HRT in their postmenopausal patients. This 
answer may indicate that these nephrology health care 
providers do lack the ability to assess, manage, and 
evaluate the use of HRT. Providers also tended to 
prescribe HRT only when they had to for surgically-induced 
menopause and when patients ask for it were ranked as the 
number one and two reasons to prescribe HRT by these 
health care providers.
Conclusion
Nephrology health care providers identified 
facilitators of HRT prescription as surgically-induced 
menopause and the need for more research of HRT among 
women with renal failure. Nephrology health care providers 
ranked concern of liability as the number one barrier to 
HRT prescription. Clearly the health care provider sample
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is not prevention care focused nor are they aware of 
current positive research of benefits associated with HRT. 
These findings and this researcher's position are neither 
supported nor refuted in the literature.
Eleven (42.31%) of the male health care providers 
identified that 6 to 10% of their eligible postmenopausal 
women were receiving HRT, while the 2 female health care 
providers identified that > 50% (7.6%) of their eligible 
female patients were on HRT. This finding supports the 
Health Promotion Model (Pender, 1996) in that modifying 
factors, such as race, gender, or age, are factors that 
directly impact health-promoting behaviors. This finding 
also supports Gillen et al. (1999) who cited physician 
attitude, ethnicity, secular trends, and geographical 
location as factors, which might explain the overall low 
prescription rate of HRT among women with renal failure.
The researcher recognized two potential limitations 
that may have impacted study results: a potential sample 
bias due to limited geographic setting and small sample 
size and methodological concerns.
Implications for Nursing
Practice. The documented benefits of HRT have 
significance for postmenopausal women with ESRD disease. 
The younger age for entering menopause in this population
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of patients removes the protective cardiovascular, 
cognitive, and bone mass effects of estrogen. Women with 
ESRD have a higher risk for cognitive dysfunction, renal 
osteodystrophy, accelerated atherosclerosis, and 
cardiovascular disease compared to the general population. 
Cardiovascular disease accounts for nearly half of the 
mortality in dialysis patients each year. The potential 
benefits of HRT for women with ESRD are numerous. The 
cardiovascular protective effects alone could 
significantly decrease related morbidity and mortality as 
well as a substantial decrease in associated health care 
costs (Gipson, 1999). Nephrology health care providers are 
in a unique position to initiate HRT as physicians and 
nurse practitioners see dialysis patients on a weekly 
basis. By viewing HRT as preventive medicine, these health 
care providers could dramatically impact related morbidity 
and mortality in postmenopausal women with ESRD as well as 
improve their quality of life by decreasing depression and 
enhancing mood. Nurse practitioners' are educated to 
assess and treat the woman holistically. The nephrology 
nurse practitioner could augment the care of the 
nephrologist by initiating and monitoring with HRT and 
providing teaching, counseling, and prevention reflecting 
contraception, pregnancy, and menopause.
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Research. Advanced practice nurses in nephrology 
should conduct more research regarding benefits of HRT 
prescription to postmenopausal women with renal failure. 
The current researcher clearly identified this need as it 
was ranked as the number one external facilitator to HRT 
initiation. The importance of publishing and presenting 
this research at regional and national Nephrology meetings 
is crucial.
Theorist. Pender's Health Promotion Model identifies 
cognitive-perceptual factors that influence care providers 
to initiate behaviors that are focused on health promotion 
and disease prevention. Nephrology health care providers 
clearly have ignored the use of HRT as both disease 
prevention and health enhancing. The beliefs of nephrology 
health care providers about primary prevention, importance 
of health, and perceived benefits to health-promoting 
behaviors are concepts from the Health Promotion Model 
that are applicable to this study. Health care providers 
working in nephrology must buy into the perceived benefits 
of HRT. According to Pender, endorsing this concept would 
make them more apt to refer, teach, counsel, and assess 
their postmenopausal patients for signs of estrogen 
deficiency. Another concept in the Health Promotion Model 
is importance of health; if health care providers 
recognized HRT as important to health, they would be more
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apt to prescribe. If they support the benefits of HRT, 
this can be either a facilitator or a barrier.
Recommendations
Based on the findings of this study, the following 
recommendations were made:
Research
1. Replication of this study with a larger sample 
including more women providers.
2. Replication of this study with an instrument which 
has established validity and reliability.
3. Development of outcome measures for CEUs which has 
a focus on HRT for all nephrology health care providers.
Nursing practice
1. Initiation of HRT as a primary prevention strategy 
for postmenopausal women with renal failure by nephrology 
nurse practitioners.
2. Avocation by Nurse Practitioners working in 
nephrology for all female patients with ESRD to have 
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Please answer the following questions by filling in the blank or 
placing a check (#/) by the appropriate answer.
1. Are you a 
O  a. MD
O  b. Board certified nephrologist 
ni c. NP
In the state of (please check one)
O  a. Alabama
0  b . Mississippi
01 c. Tennessee
If NP, please indicate clinical speciality area of NP preparation 
and any additional certifications or specialty training in the 
nephrology field.
Years practicing as a nephrology health care provider:
Gender 
O  a. Male 
O  b. Female
3. Please estimate the total number of patients you care for:
CÜ3 a. Less than 100 O  f. 501 to 600
O  b. 101 to 200 O  g. 601 to 700a c. 201 to 300 O  h. 701 to 800
O  d. 301 to 400 i. More than 800
4. Please estimate the number of female patients age 47 and older 
whom you care for:____________________________________________
5. Of these patients, what percent are on any form of estrogen 
replacement?
O  a. 0 01 g. 26 to 30%
O b. 1 to 5% O
O c. 6 to 10% O
O d. 11 to 15% O
O e. 16 - 20% O
O f- 21 to 25% O
h. 31 to 35%
i. 36 to 40% 
j. 41 to 45% 
k. 46 to 50%
1. More than 50%
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6. Please approximate how many CEUs youin the last year:O a. 0 □  e.O b. 1 to 5 □  f.C] c. 6 to 10 d g.
d. 11 to 15 id h.
Last 5 years :
L J  a. 0 id e.d b. 1 to 5 d f.d c. 6 to 10 d g.d d. 11 to 15 d h.
16 to 20 
21 to 25 
26 to 30 
More than 31
16 to 20 
21 to 25 
26 to 30 
More than 31
For the following 3 questions, please rank in order of importance:
7. Reasons you would initiate HRT in postmenopausal women under your 
care :
_____ a. Relief of menopausal symptoms such as decreased libido,
depression, mood swings, and hot flashes.
_____ b. Prevention of osteoporosis
_____ c. Cardiovascular protective effects
_____ d. Patients ask for it
_____ e. Surgically-induced or premature menopause
f. Other. Comments:
8. Reasons you would not initiate HRT in postmenopausal women under 
your care :
_____  a. View as primary care or as gyn specialty
_____  b. Physician liability; concerns with patient compliance
with follow-up care (pap smear)
_____  c. Concerns about adverse effects of HRT in your patients
_____  d. Client has preexisting cardiovascular disease.
_____  e. Unsure of what type and dose to prescribe
f. Other. Comments:
9. What would make it easier or more convenient for you to prescribe 
HRT?
__  a. CEUs
_____  b. Pocket Guide
_____ c. More research concerning benefits and or adverse 
reactions in ESRD patients 
_____  d. Journal articles
_____  e. Presentations at national/international meetings
f. Other. Comments:
10. Please feel free to make any comments relevant to this research 
study:
APPENDIX C 




26 CR 403 
Oxford, MS 38655
Dear Head Nurse or Charge Nurse,
I am a nephrology nurse of 18 years and a graduate student 
at Mississippi University for Women. I am conducting a 
research study about hormone replacement therapy (HRT) in 
postmenopausal women with ESRD. I have found a limited 
amount of research literature concerning benefits and or 
specific risk factors in this population of patients.
I have enclosed 5 copies of a questionnaire concerning 
HRT. Would you please give each nephrologist and or nurse 
practitioner a packet? If they would like to participate 
in the study, please ask each one to fill out the 
questionnaire and return it in the enclosed self- 
addressed, stamped envelope. Return of the questionnaire 
implies consent. Participation is voluntary, and 
confidentiality will be maintained as no identifying names 
will appear on the forms.
The majority of female patients are postmenopausal, and 
this in itself has many health-related problems. These 
problems compact the already complicated medical issues 
that our patients must deal with on a daily basis. It is 
my desire to research this area in hopes of improving the 
quality of life for these women.
Thank you in advance for your time and participation; 
coming from a hemodialysis background for many years, I 








Dear Head Nurse or Charge Nurse,
Just a friendly reminder about the questionnaire 
concerning hormone replacement therapy in your 
postmenopausal patients. Your input is much needed 
and appreciated. If you have completed and returned 
the questionnaire, thank you for your participation. 
If you have not, please consider doing so.
Again, thank you in advance for taking 









26 CR 403 
Oxford, MS 38655
Dear Nephrology Health Care Provider,
I am a nephrology nurse of 18 years and a graduate student 
at Mississippi University for Women in Columbus, 
Mississippi. I am conducting a research study about hormone 
replacement therapy (HRT) in postmenopausal women with ESRD 
and would like for you to participate in my study.
Enclosed please find a survey that I am using for my 
research study. If you would like to participate, please 
complete the questionnaire and return in the enclosed self- 
addressed, stamped envelope. Return of the questionnaire 
implies consent. Participation is voluntary, and 
confidentiality will be maintained as no identifying names 
will appear on the forms.
Thank you in advance for your time and participation; 
coming from a hemodialysis background for many years, I 
realize how busy you are, and I am deeply grateful for your 
assistance.
Sincerely,
Lynn Trame1
